Erratum: Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase ii checkmate 205 trial(J Clin Oncol DOI: 10.1200/JCO.2017.76.0793);Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II checkmate 205 trial

Journal of Clinical Oncology

Volumn 36, Issue 14, 2018, Pages 1428-1439

  Armand, Philippe ^a   Engert, Andreas ^b   Younes, Anas ^c   Fanale, Michelle ^d   Santoro, Armando ^e   Zinzani, Pier Luigi ^f   Timmerman, John M ^g   Collins, Graham P ^h   Ramchandren, Radhakrishnan ⁱ   Cohen, Jonathon B ^j   De Boer, Jan Paul ^k   Kuruvilla, John ^l   Savage, Kerry J ^m   Trneny, Marek ⁿ   Shipp, Margaret A ^a   Kato, Kazunobu ^o   Sumbul, Anne ^o   Farsaci, Benedetto ^o   Ansell, Stephen M ^p  

^a Dana Farber Cancer Institute   (Morocco)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UCLA MEDICAL CENTER   (United States)

^h CHURCHILL HOSPITAL   (United Kingdom)

ⁱ KARMANOS CANCER INSTITUTE   (United States)

^j EMORY UNIVERSITY   (United States)

^k ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^l UNIVERSITY OF TORONTO   (Canada)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o BRISTOL MYERS SQUIBB   (United States)

^p MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BRENTUXIMAB VEDOTIN; NIVOLUMAB; TRIACYLGLYCEROL LIPASE; ANTIBODY CONJUGATE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; NORTH AMERICA; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIVOLUMAB; NORTH AMERICA; TREATMENT OUTCOME;

EID: 85045947562     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2018.79.3547     Document Type: Erratum

References (33)

1. von Tresckow B, Müller H, Eichenauer DA, et al: Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 55:1922-1924, 2014
2. Crump M: Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008: 326-333, 2008
3. Moskowitz AJ, Perales MA, Kewalramani T, et al: Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 146:158-163, 2009
4. Bartlett NL, Niedzwiecki D, Johnson JL, et al: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 18: 1071-1079, 2007
5. Moskowitz AJ, Hamlin PA Jr, Perales MA, et al: Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 31:456-460, 2013
6. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183-2189, 2012
7. Chen R, Gopal AK, Smith SE, et al: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128:1562-1566, 2016
8. Green MR, Monti S, Rodig SJ, et al: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268-3277, 2010
9. Roemer MG, Advani RH, Ligon AH, et al: PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690-2697, 2016
10. Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034, 2000
11. Latchman Y, Wood CR, Chernova T, et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261-268, 2001
12. Bristol-Myers Squibb: Opdivo (nivolumab) Highlights of prescribing information. http://packageinserts.bms.com/pi/pi_opdivo.pdf
13. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311-319, 2015
14. Younes A, Santoro A, Shipp M, et al: Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17: 1283-1294, 2016
15. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
16. Bredeson C, LeRademacher J, Kato K, et al: Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 122:3871-3878, 2013
17. Bajaj G, Wang X, Agrawal S, et al: Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol 6:58-66, 2017
18. Saliba RM, de Lima M, Giralt S, et al: Hyper-acute GVHD: Risk factors, outcomes, and clinical implications. Blood 109:2751-2758, 2007
19. European Medicines Agency: Annex I: Opdivo (nivolumab) Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/ WC500189765.pdf
20. Chen R, Zinzani PL, Fanale MA, et al: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35:2125-2132, 2017
21. Seattle Genetics: Adcetris (brentuximab vedotin) prescribing information, November 2017. http://www.seattlegenetics.com/application/files/2515/1059/6728/ ADCETRIS_USPI_USP-BVP-2015-01625pdf.pdf
22. Hodi FS, Hwu WJ, Kefford R, et al: Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34:1510-1517, 2016
23. Wolchok JD, Hoos A, O’Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
24. Long GV, Weber JS, Larkin J, et al: Nivolumab for patients with advanced melanoma treated beyond progression: Analysis of 2 phase 3 clinical trials. JAMA Oncol 3:1511-1519, 2017
25. Cheson BD, Ansell S, Schwartz L, et al: Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489-2496, 2016
26. Younes A, Hilden P, Coiffier B, et al: International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 28: 1436-1447, 2017
27. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3067, 2014
28. Anderlini P, Saliba RM, Ledesma C, et al: Gemcitabine, fludarabine, and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 22:1333-1337, 2016
29. Devetten MP, Hari PN, Carreras J, et al: Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 15:109-117, 2009
30. Marcais A, Porcher R, Robin M, et al: Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: A retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 98:1467-1475, 2013
31. Robinson SP, Sureda A, Canals C, et al: Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: Identification of prognostic factors predicting outcome. Haematologica 94:230-238, 2009
32. Sureda A, Robinson S, Canals C, et al: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:455-462, 2009
33. Merryman RW, Kim HT, Zinzani PL, et al: Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 129:1380-1388, 2017